Suggested remit - To appraise the clinical and cost effectiveness of ofatumumab within its marketing authorisation for treating relapsing forms of multiple sclerosis.
 
Status In progress
Process STA 2018
ID number 1677

Provisional Schedule

Committee meeting: 1 04 February 2021

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Consultees

Companies sponsors Novartis (ofatumumab)
Others Department of Health and Social Care
  NHS Rotherham CCG
  NHS Surrey Downs CCG
  NHS England
  Welsh Government
Patient carer groups Brain Charity
  Brain and Spine Foundation
  MS-UK
  Multiple Sclerosis National Therapy Centres
  Multiple Sclerosis Society
  Multiple Sclerosis Trust
  Muslim Council of Britain
  Neurological Alliance
  Shift.ms
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Sue Ryder
Professional groups Association of British Neurologists
  British Association of Neuroscience Nurses
  British Geriatrics Society
  British Neuropathological Society
  British Society of Rehabilitation Medicine
  Chartered Society of Physiotherapy
  Institute of Neurology
  Primary Care and Community Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Occupational Therapists
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Therapists in MS (TIMS)
  UK Clinical Pharmacy Association
  UK Multiple Sclerosis Specialist Nurse Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Bayer (interferon beta-1b)
  Biogen Idec (dimethyl fumarate, interferon beta-1a, natalizumab, peginterferon beta-1a)
  Celgene (ozanimod)
  Merck (interferon beta-1a, cladribine)
  Mylan (glatiramer acetate)
  Novartis (interferon beta-1b, fingolimod, siponimod)
  Roche (ocrelizumab)
  Sanofi Genzyme (alemtuzumab, teriflunomide)
  Teva UK (glatiramer acetate)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Multiple Sclerosis Society Wales
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research UK
  British Neurological Research Trust
  Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
08 July 2020 In progress. In progress
02 June 2020 Invitation to participate
07 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
27 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
19 November 2019 - 17 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance